海外の舌癌治療のベスト医師 — ページ3

標的型がん治療と免疫療法を専門とするムトル医師は、Medical Park Antalyaにて舌がん治療に高度なアプローチを提供しています。

• アクデニズ大学および米国で腫瘍内科の研修を修了
• 個別化がん治療のための次世代遺伝子研究の専門家
• 化学療法プロトコルにおいて豊富な経験を持つ准教授
• 主要な腫瘍学センターであるMedical Park Antalya病院複合施設に勤務

アレムダル医師は、舌がんを専門とする腫瘍内科医であり、アクデニズ大学で広範なトレーニングを受けています。

• 2018年より腫瘍内科の認定医
• 腫瘍学および内科で_doctor_9570_年以上の経験
• メディカル・パーク・アンタルヤ病院コンプレックスにて勤務

イルファン・ジチン医師は、イスティニエ大学リヴ病院トプカプの腫瘍内科教授です。膠芽腫、肺がん、膵臓腫瘍などの複雑な癌の治療を専門としています。トラキア大学医学部の教授も務めています。ジチン医師は以前、トルコ空軍の医師として勤務していました。

• 免疫療法、化学療法、ホルモン療法などの全身療法を行います。
• 婦人科、整形外科、神経腫瘍学の症例を含む幅広い疾患を治療します。
• 肝臓および腹部の悪性腫瘍に対するHIPEC（腹腔内温熱化学療法）および化学塞栓術の専門家です。
• 33の診療科を持つ300床の大学病院で勤務しています。

モハメド・マフムード・アブデルハキム博士は、カイロ大学国立がん研究所の放射線腫瘍学教授です。シェファ・アル・オルマン病院の放射線腫瘍科部長を務めています。アブデルハキム博士は、乳がん、軟部組織肉腫、婦人科腫瘍など、複雑ながんの治療を行っています。ESTROおよびESMOの会員です。

• 画像誘導小線源治療および定位放射線治療を実施。
• IMRT、VMAT、SRS、SBRTを用いて腫瘍を精密に標的化。
• 骨髄移植のための全身および全身皮膚照射を提供。
• ESMO認定を受けたルクソールのシェファ・アル・オルマン病院で診療。

マハ・ヤヒア博士は、シェファ・アル・オルマン国際腫瘍病院の腫瘍内科医兼血液内科医です。エジプト軍医療隊で中佐の医師として勤務した経験があります。ヤヒア博士は、乳がん、胸部がん、消化器がんの治療計画を専門としています。免疫療法、分子標的療法、複雑な化学療法プロトコルに注力しています。

• マーディ軍事医療センター（Maadi AFMC）の臨床研究支援チームの元リーダー。
• カイロ大学国立がん研究所で血液腫瘍学の研修を修了。
• 泌尿器がん、婦人科がん、希少がん、および血液疾患の治療を行う。
• 年間6,000人の患者を治療するESMO認定センターに勤務。

エマド・シャシュ医師は、70件以上の腫瘍学臨床試験に参加した腫瘍内科医です。NCIの乳がん総合病院で医療ディレクターを務めています。シャシュ医師は、化学療法、分子標的療法、免疫療法を含む全身療法を専門としています。JCIの病院品質管理および患者安全に関するディプロマを保持しています。

• ESMOパネルの投票権を持つメンバーであり、ASCO委員会のメンバーでもあります。
• 乳がん、婦人科がん、泌尿生殖器がん、胸部がん、消化器がん、および希少がんを治療しています。
• ブリュッセルのEORTCで元研究医師および医療リーダーを務めました。
• 年間6,000人の患者を治療するESMO認定腫瘍学センター、Shefaa Al Ormanで勤務しています。

Zhang Jinshan, male, China’s First M.D. in the Radiation Medicine, CCI (Chinese College of Interventionalists) Master Interventionalist, Director of the Department of Former Radiological Diagnosis at Chinese PLA General Hospital(No.3 in China) Ph.D. of Medicine, Nagasaki University, Japan.

1980–1985: Completed doctoral studies at Nagasaki University, Japan

1968–present: Department of Radiology, Chinese PLA General Hospital

1988: Third Prize of the Military Science and Technology Progress Award

1989–present: Member of Radiological Society of North America(RSNA)

1990–2009: Standing Committee Member of the Radiology and Therapeutic Radiology Committee of the PLA

1991: Second Prize of the Military Science and Technology Progress Award

1992–2008: Group Leader of the Group of Intervention of Chinese Journal of Radiology

1992–2015: Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

1993: Granted the Lifetime Special Government Allowance of the State Council

1993–2012: Deputy Chief Editor of Chinese Journal of Medical Image Technology

1994: Third Prize of the Military Science and Technology Progress Award

1997: Second Prize of the Military Science and Technology Progress Award

1997–2009: Standing Member of Chinese Society of Radiology

1999: Third Prize of the Military Science and Technology Progress Award

1999–2010: Deputy Director Member of Chinese Society of Interventional Oncology

2002: Second Prize of the Military Science and Technology Progress Award

2005: Third Prize of the Military Science and Technology Progress Award

Member of Radiological Society of North America(RSNA)

Standing Member of Chinese Society of Radiology

Group Leader of the Group of Intervention of Chinese Journal of Radiology

Deputy Director Member of Chinese Society of Interventional Oncology

Director Member of Beijing Medical Association Society of Interventional Radiology

Deputy Chief Editor of Chinese Journal of Medical Image Technology

Standing Member of Professional Committee of Radiological Medicine of the Chinese People’s Liberation Army

Standing Editorial Board Member and Editorial Board Member of Journal of Interventional Radiology

Awarded the Special Government Allowance of the State Council

Awarded three Second Prizes and four Third Prizes for Military Science and Technology Progress.

Awarded the honorary title of “Chinese College of Interventionalists(CCI) Master Interventionalist”

Led multiple national and provincial/ministerial scientific research projects, including two projects funded by the National Natural Science Foundation of China and two projects funded by the Department of Science and Technology of Sichuan Province.

In the pioneering development of interventional medicine in China, Zhang Jinshan has been an indispensable founder and leading figure. As China’s first overseas-trained doctoral graduate in radiological medicine, he returned to China in the 1980s after completing his studies abroad and introduced cutting-edge international interventional technologies to the country. Over more than four decades of dedicated practice and research, he has helped propel Chinese interventional medicine from its infancy to a position at the forefront of the global field through his exceptional clinical expertise and profound academic accomplishments.

Professor Zhang Jinshan has long been dedicated to the field of medical imaging and has developed distinctive expertise in selective and superselective interventional diagnosis and treatment for solid tumors such as liver cancer, demonstrating exceptional technical proficiency and profound academic accomplishment. Beginning in the 1990s, he led his team in pioneering the clinical application and research of TIPSS and B-ORTO in China, filling major gaps in the domestic field and opening new paths for the interventional management of gastrointestinal bleeding caused by portal hypertension secondary to liver cirrhosis. In addition, he has made groundbreaking contributions to the interventional diagnosis and treatment of peripheral vascular diseases, as well as to preoperative embolization for spinal tumors.

In the field of liver cancer treatment, Professor Zhang Jinshan not only led the development of standardized treatment protocols for liver cancer but also pioneered Transcatheter Arterial Chemoembolization with temporary Hepatic Vein Thrombosis (TACE-THVO) for primary liver cancer, bringing the efficacy of interventional therapy to a new level. In recognition of his outstanding clinical and scientific contributions, he was awarded the honorary title of “Chinese Master of Interventional Radiology” at the 2019 annual conference of the Chinese College of Interventionalists.

Professor Zhang Jinshan is not only a master clinician but also a driving force in the development of the discipline and a dedicated mentor in talent cultivation. He led his team in establishing one of China’s premier interventional therapy centers. As a doctoral supervisor, he has trained a large number of outstanding specialists and future leaders in interventional medicine, with many of his students and protégés now serving across the country. Academically, he has led multiple key national and military research projects, published more than 300 academic papers, and served as chief editor of three monographs, making remarkable contributions to the establishment of China’s academic framework for interventional medicine and the nationwide dissemination of its technologies.

From the laboratory to the operating room, and from academic podiums to grassroots hospitals, Professor Zhang Jinshan has consistently upheld the principles of “pioneering, innovation, pragmatism, and compassion". He has devoted his life to fulfilling the mission of a physician—relieving patients’ suffering through minimally invasive techniques and advancing the discipline through academic excellence—thereby establishing himself as a truly towering figure and one of the foremost authorities in the field of interventional medicine in China.

Professor Zhang Jinshan’s Academic Achievements

Professor Zhang Jinshan has achieved prolific academic accomplishments, having published over 300 academic papers covering areas such as interventional therapy for liver cancer, minimally invasive treatment of portal hypertension, interventional treatment of vascular diseases, and tumor ablation.

Selected Publications by Professor Zhang Jinshan

1. Zhang Jinshan, Wang Maoqiang. Experiments and Clinical Studies of transjugular intrahepatic portosystemic stent shunt (TIPSS). Chinese Journal of Radiology, 1993，27（6）：361-365.

Professor Zhang Jinshan is the first author. This is one of the early research papers in China that systematically elaborates on the TIPSS technique. Through animal experiments and clinical case analysis, it confirmed that TIPSS is a safe and effective minimally invasive method for treating portal hypertension and its complications, laying an important foundation for the promotion and application of this technique in China.

2.Zhang Jinshan, Li Huai. Clinical study on transcatheter arterial embolization with temporary hepatic vein occlusion for the treatment of primary liver cancer.Chinese Journal of Radiology, 1996，30（8）：521-524.

Professor Zhang Jinshan is the first author. He innovatively proposed the technique of "transcatheter arterial embolization with temporary hepatic vein occlusion." Clinical results demonstrated that this method can significantly increase the drug concentration within liver cancer lesions, reduce damage to normal liver tissue, and effectively improve the therapeutic outcomes for intermediate and advanced liver cancer, providing a novel strategy for the interventional treatment of liver cancer.

3. Zhang Jinshan, Wang Maoqiang, Li Huai. Interventional treatment of Budd-Chiari syndrome. Chinese Journal of Medical Imaging Technology, 1998，14（3）：189-191.

Professor Zhang Jinshan is the first author. This paper systematically summarizes the early experience in interventional treatment of Budd-Chiari syndrome in China, elaborating in detail on the key operational points and therapeutic efficacy of techniques such as percutaneous transluminal angioplasty and stent placement. It confirms that interventional therapy is the preferred minimally invasive method for Budd-Chiari syndrome, promoting the standardized development of treatment for this disease.

4.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical value of superselective hepatic arterial chemoembolization in the treatment of hypovascular liver cancer. Chinese Journal of Radiology, 2000，34（5）：335-337.

Professor Zhang Jinshan is the first author. Addressing the challenges in interventional treatment of hypovascular liver cancer, this paper explores the clinical efficacy of superselective hepatic arterial chemoembolization. The results indicate that this technique can precisely target the lesions and improve the treatment response rate, providing an important clinical basis for the interventional treatment of hypovascular liver cancer.

5. Zhang Jinshan, Li Huai, Wang Maoqiang. Interventional treatment of peripheral vascular stenosis and occlusion.Chinese Journal of Radiology, 2002，36（7）：612-614.

Professor Zhang Jinshan is the first author. This paper summarizes the interventional treatment experience of over 400 patients with peripheral vascular stenosis and occlusion, analyzing the indications and efficacy of techniques such as balloon angioplasty and stent placement. It confirms that interventional therapy is a safe and effective approach for peripheral vascular diseases, providing practical support for its clinical promotion.

6.Zhang Jinshan, Li Huai, Wang Maoqiang. Clinical application of CT-guided percutaneous puncture ablation in the treatment of abdominal tumors. Chinese Journal of Medical Imaging Technology, 2004，20（9）：1395-1397.

Professor Zhang Jinshan is the first author. This paper explores the application value of CT-guided percutaneous puncture techniques such as radiofrequency ablation and chemical ablation in the treatment of abdominal tumors. The clinical results show that this method is minimally invasive with reliable efficacy, offering a minimally invasive treatment option for patients with inoperable abdominal tumors.

7.Zhang Jinshan, Wang Maoqiang, Li Huai. Advances in the application of interventional therapy for benign prostatic hyperplasia. Chinese Journal of Radiology, 2006，40（8）：876-878.

Professor Zhang Jinshan is the corresponding author. This paper systematically reviews the cutting-edge advances in interventional therapy for benign prostatic hyperplasia, including the principles, procedures, and efficacy of techniques such as prostatic artery embolization and stent placement, providing new insights for the minimally invasive treatment of benign prostatic hyperplasia.

8.Zhang Jinshan, Li Huai, Wang Maoqiang. Discussion on the standardization of interventional therapy for liver cancer. Chinese Journal of Practical Surgery, 2008，28（10）：856-858.

Professor Zhang Jinshan is the corresponding author. Drawing on years of clinical experience and research findings, he led the discussion on standardized protocols for interventional therapy of liver cancer, covering key aspects such as preoperative assessment, treatment modality selection, and postoperative management, providing important references for the formulation of clinical guidelines for interventional therapy of liver cancer in China.

Professor Zhang Jinshan co-authored monographs

1. Interventional Radiology (People's Military Medical Press, 1995): The first monograph in China to systematically discuss the theories and techniques of interventional radiology. It comprehensively elaborates on the interventional diagnosis and treatment system for tumors, vascular diseases, and non-vascular diseases, becoming a classic essential textbook for interventional physicians in China.

2.Interventional Therapy for Liver Cancer (People's Health Press, 2001): Focusing on minimally invasive interventions for liver cancer, this book systematically summarizes techniques such as TACE, ablation, and vascular intervention, refines operational standards and the prevention and management of complications, and promotes the standardization of interventional therapy for liver cancer.

3.Interventional Treatment of Portal Hypertension (Science Press, 2005): This book systematically elaborates on minimally invasive techniques for portal hypertension, such as TIPSS and B-ORTO, covering experimental research, clinical procedures, long-term follow-up, and efficacy evaluation, filling the gap in monographs on interventional treatment of portal hypertension in China.

Professor Zhang Jinshan’s Research project

1.The National "Eighth Five-Year Plan" Scientific and Technological Key Project—Clinical and Basic Research on Comprehensive Interventional Therapy for Liver Cancer (Project Leader): This project systematically explored multimodal interventional strategies for liver cancer, established the core regimen of superselective TACE combined with local ablation, and significantly improved the therapeutic outcomes for intermediate and advanced liver cancer.

2.The Military "Ninth Five-Year Plan" Key Medical Scientific Research Project—Standardized Research on TIPSS for the Treatment of Portal Hypertension (Project Leader): This project formulated China's first operational standards and postoperative management guidelines for TIPSS, reduced the incidence of complications, and promoted the popularization of this technique throughout the military and across the country.

3.National Natural Science Foundation of China Project — Research on the Mechanism of Targeted Therapy for Liver Cancer Using Hepatic Vein Occlusion Combined with Chemoembolization (Project Leader): This project revealed the synergistic enhancement mechanisms of the innovative technique at the levels of hemodynamics, drug metabolism, and the tumor microenvironment, providing theoretical support for precision interventional therapy of liver cancer.

4.Military Clinical High-Tech Major Project-Establishment and Clinical Application of the Interventional Treatment Technology System for Complex Vascular Diseases (Project Leader): This project overcame interventional challenges in complex lesions such as Budd-Chiari syndrome, peripheral vascular occlusion, and vascular malformations, forming a complete technical system that has been promoted and applied widely.

エルカン・カラタシュ医師は、耳鼻咽喉科および頭頸部外科において高度な訓練を受けており、権威ある機関での豊富な国際経験を有しています。

• 欧米の複数のトップセンターで頭頸部外科を専門とする
• ハノーバー医科大学およびその他の主要機関で研修
• 複数の国際的な耳鼻咽喉科および頭頸部外科学会の会員

ラーナン・バーガー博士は、シェバ医療センターがんセンターのセンター長です。2025年にはForbesイスラエルの「ベストドクター」リストに選出されました。バーガー博士は泌尿器腫瘍学を専門とし、複雑な前立腺腫瘍への放射線治療を行っています。ダナ・ファーバー/ハーバードがん研究所で博士研究員としてのフェローシップを修了しました。

• 分子腫瘍学に焦点を当てた臨床研究ユニットを統括。
• 前立腺がんとBRCA変異に関する20本以上の査読付き論文の共著者。
• 米国臨床腫瘍学会（ASCO）会員。
• 世界トップ10にランクされる病院で全身療法および放射線療法を実施。

ガレニア病院の舌がん専門の認定外科腫瘍医。

• メキシコ腫瘍学会会員
• 2020年よりアナワク大学の大学教員
• 2030年までConacem認定
• Centro Medico Nacional 20 de Noviembreにて研修

エルケ・イェーガー教授は年間1,100件の処置を行っており、Focus誌のランキングで41 年にわたりドイツのトップオンコロジストの一人に選ばれています。

• 41 年の腫瘍学および血液学における専門性
• ノルトヴェスト病院腫瘍学・血液学部門長
• ゲーテ大学学際的腫瘍学教授
• 豊富な症例数を誇るトップクラスの肉腫専門医

アタカン・トプチュ医師は、イスタンブールのメディポル・アジバデム地区病院の腫瘍内科医です。肺がん、乳がん、大腸がんを含む固形腫瘍の治療を専門としています。トプチュ医師は准教授であり、50本以上の査読付き科学論文を発表しています。医学誌『BMC Cancer』の編集委員を務めています。

• 免疫療法、分子標的療法、老年腫瘍学ケアの専門知識。
• がん関連の栄養失調、悪液質、サルコペニアの治療。
• 欧州臨床腫瘍学会（ESMO）の正会員。
• 高度な腫瘍治療を専門とするJCI認定病院に勤務。

ナイル・パクソイ准教授は、メディポル・バフチェリエヴレル病院の腫瘍内科を専門とし、舌がんの治療に注力しています。

• ESMO（欧州臨床腫瘍学会）認定腫瘍内科医
• がん治療に関する複数の国際的な臨床試験に参加
• 治療の有効性を含む、腫瘍学の様々なトピックに関する研究を発表
• イスタンブール大学腫瘍学研究所にてフェローシップ修了

Ayşe İrem Yasin医師は、イスタンブールのメディポル・アジュバデム地区病院の腫瘍内科医です。権威あるESMOボード認定資格を保持しています。Yasin医師は、乳がん、肺がん、消化器がんを含む固形腫瘍を専門としています。メルケル細胞癌や原発不明がんなどの複雑な症例を治療しています。

• ハーバード大学医学大学院、クリーブランド・クリニック、バーゼル大学病院で研修。
• イタリアのノヴァーラにある乳がんユニットで臨床観察を修了。
• 脳および中枢神経系の悪性腫瘍、軟部肉腫、泌尿器がんを治療。
• da Vinciロボットシステムを備えたJCI認定施設で勤務。